Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East
Journal of Allergy and Clinical Immunology: Global · 2026-07 · 5 (4) · 100705
DOI: 10.1016/j.jacig.2026.100705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2026-07. Verfasst von Shuayb Elkhalifa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
- University of Manchester, Manchester, United Kingdom.
Zitieren
APA
Elkhalifa, S., Mahmoud, E., Salvo, F., AlHameli, H., Cerecedo, I., Shafiq, I., & Abuzakouk, M. (2026). Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East. Journal of Allergy and Clinical Immunology: Global, 5(4), 100705. https://doi.org/10.1016/j.jacig.2026.100705
Vancouver
Elkhalifa S, Mahmoud E, Salvo F, AlHameli H, Cerecedo I, Shafiq I, et al. Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East. Journal of Allergy and Clinical Immunology: Global. 2026;5(4):100705. doi:10.1016/j.jacig.2026.100705
BibTeX
@article{Elkhalifa2026,
author = {Elkhalifa, Shuayb and Mahmoud, Eiman and Salvo, Fulvio and AlHameli, Hamad and Cerecedo, Inmaculada and Shafiq, Irfan and Abuzakouk, Mohamed},
title = {Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2026},
volume = {5},
number = {4},
pages = {100705},
doi = {10.1016/j.jacig.2026.100705}
}
EUVIMED